MAP2K7 and melanoma: MEK is a kinase enzyme downstream to RAF that may be constitutively active in up to 8% of melanomas [6] and can be targeted with MEK inhibitors (MEKi) – such as Trametinib, Binimetinib, and Cobimetinib.